Abstract

Introduction: We have demonstrated that the P2X7 receptor (P2RX7), which activates immune cells via binding of extracellular adenosine triphosphate, plays a role in hypertension and vascular injury. Angiotensin (Ang) II-induced hypertension, vascular injury and perivascular infiltration of activated CD8 + T cells were attenuated by P2rx7 knockout or P2RX7 pharmacologic blockade. However, whether P2RX7 is involved in Ang II-induced cardiac dysfunction and hypertrophy remains unknown. Hypothesis: We hypothesized that Ang II-induced left ventricular (LV) dysfunction and hypertrophy will be blunted equally by P2rx7 knockout and P2RX7 antagonism. Methods: Ten-to-12-week-old male C57BL/6J wild-type (WT) and P2rx7 -/- mice were infused or not with Ang II (1000 ng/kg/min) for 14 days. A second group of WT mice infused with Ang II was infused with the P2RX7 antagonist AZ10606120 (694 ng/kg/min) or vehicle for 14 days. Cardiac LV function and remodeling were determined by ultrasound, and hypertrophic markers in cardiac ventricles by reverse transcription-quantitative PCR (RT-qPCR). Results: Ang II-induced increase in LV mass/body weight (6.3±0.2 vs 4.2±0.2 mg/g, P <0.001) and decrease in fractional shortening in WT mice (32.5±3.1% vs 43.8±2.4%, P <0.05) were exaggerated in P2rx7 -/- mice (7.3±0.5 mg/g and 20.2±3.1%, P <0.05), but not in mice receiving AZ10606120 (6.2±0.4 mg/g and 28.9±3.3%). Ang II-induced atrial natriuretic peptide ( Nppa /ribosomal protein S16 [ Rps16 ], 6.8±2.3 vs 1±0.1, P <0.001) and α-skeletal actin 1 expression ( Acta1 / Rps16 , 6.3±1.3 vs 1±0.2, P <0.001) tended to be further increased in P2rx7 -/- mice ( Nppa / Rps16 : 13.5±2.4 and Acta1 / Rps16 : 11.9±2.4), but not in AZ10606120-treated mice ( Nppa / Rps16 : 5.5±0.7 and Acta1 / Rps16 : 5.6±0.8). Conclusion: Ang II-induced LV hypertrophy and dysfunction were exaggerated by P2rx7 knockout but were not affected by P2RX7 pharmacologic blockade.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.